Antibody therapy for rheumatoid arthritis

Current Opinion in Pharmacology

Volumn 3, Issue 3, 2003, Pages 323-328

  Taylor, Peter C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; B7 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; KELIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNINDEXED DRUG;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; B LYMPHOCYTE; CHIMERA; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; GENE INTERACTION; HUMAN; JOINT INJURY; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; INFLAMMATION; RANDOMIZED CONTROLLED TRIALS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038516689     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00032-8     Document Type: Review

References (43)

1. Sharp J.T. Wolfe F. Mitchell D.M. Bloch D.A.The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease Arthritis Rheum. 34 1991 660-668.
2. Maini R.N. Taylor P.C. Anti-cytokine therapy in rheumatoid arthritis Annu. Rev. Med. 51 2000 207-229.
3. Barrera P. Joosten L.A. den Broeder A.A. van de Putte L.B. van Riel P.L .van den Berg W.B. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis Ann. Rheum. Dis. 60 2001 660-669.
4. Den Broeder A.A. van de Putte L. Rau R.Schattenkirchner M. Van Riel P. Sander O. Binder C. Fenner H. Bankmann Y. Velagapudi R. et al. A single dose, placebo conrolled study of the fully human anti-necrosis factor alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis J. Rheumatol. 29 2002 2288-2298.
5. Choy E.H.S. Hazleman B. Smith M. Moss K. Lisi L. Scott D.G.I. Patel J. Sopwith M. Isenberg D.A. Efficacy of a novel PEGylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial Rheumatology 41 2002 1133-1137.
6. Davis M.W. Feige U. Bendele A.M. Martin S.W. Edwards C.K.III Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update Ann. Rheum. Dis. 59Suppl 1 2000 41-43.
7. Maini R.N. St Clair E.W. Breedveld F. Furst D. Kalden J. Weisman M. Smolen J. Emery P. Harriman G. et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial Lancet 354 1999 1932-1939.
8. Lipsky P.E. van der Heidje D.M.F.M. St Clair E.W. Furst D. Breedveld F. Kalden J. Smolen J. Weisman M. Emery P. Feldmann M. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis N. Engl. J. Med. 343 2000 1594-1602.
9. Weinblatt M.E. Kremer J.M. Bankhurst A.D. Bulpitt K.J. Fleischmann R.M. Fox R.I. Jackson C.G. Lange M. Burge D.J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N. Engl. J. Med. 340 1999 253-259.
10. Rau R. Adalimumab (a fully human anti-tumour necrosis factor a monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials Ann. Rheum. Dis. 61Supp 2 2002 70 73
11. Shergy W.J. Isern R.A. Cooley D.A. Harshbarger J.L. Huffstutter J.E. Hughes G.M. Spencer-Smith E.A. Goldman A.L. Roth S.H. Toder J.S. et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis J. Rheumatol. 29 2002 667-677.
12. Bathon J.M. Martin R.W. Fleischmann R.M. Tesser J.R. Sciff M.H. Keystone E.C. Genovese M.C. Wasko M.C. Moreland L.W. Weaver A.L. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N. Engl. J. Med. 343 2000 1586-1593.
13. Den Broeder A.A. Joosten L.A. Saxne T. Heinegard D. Fenner H. Miltenburg A.M. Frasa W.L. van Tits L.J. Buurman W.A. van Riel P.L. et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation Ann. Rheum. Dis. 61 2002 311-318.
14. Genovese M.C. Bathon J.M. Matin R.W. Fleischmann R.M. Tesser J.R. Schiff M.H. Keystone E.C. Wasko M.C. Moreland dL.W. Schiff M.H. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes Arthritis Rheum. 46 2002 1443-1450.
15. Taylor P.C. Anti-TNF therapies Curr. Opin. Rheum. 13 2001 164-169.
16. Maini R.N. Breedveld F.C. Kalden J.R. Smolen J.S. Davis D. Macfarlane J.D. Antoni C. Leeb B. Elliott M.J. Woody J.N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum. 41 1998 1552-1563.
17. Garrison L. McDonnell N.D. Etanercept: theapeutic use in patients with rheumatoid arthritis Ann. Rheum. Dis. 58Suppl 1 1999 165-169.
18. Kiely P.D. Johnson D.M. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study Rheumatology (Oxford) 41 2002 631-637.
19. St Clair E.W. Wagner C.L. Fasanmade A.A. Wang B. Sciable T. Kavanaugh K. Keystone E.C. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis Arthritis Rheum. 46 2002 1451-1459.
20. Den Broeder A.A. Creemers M.C. van Gestel A.M. van Riel P.L. Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha Rheumatology (Oxford) 41 2002 638-642.
21. Keane J. Gershon S. Wise R.P. Mirabile-Levens E. Kasznica J. Schwieterman W.D. Siegel J.N. Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N. Engl. J. Med. 345 2001 1098-1104.
22. Geborek P. Crnkic M. Petersson I.F. Saxne T. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden Ann. Rheum. Dis. 61 2002 793-798.
23. Charles P. Smeenk R.J.T. DeJong J. Feldmann M. Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Findings in open-label and randomized placebo-controlled trials Arthritis Rheum. 43 2000 2383-2390.
24. Shakoor N. Michalska M. Harris C.A. Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy Lancet 359 2002 579-580.
25. Mikuls T.R. Moreland L.W. Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis Drug Saf. 26 2003 23-32.
26. van de Loo A.A. Arntz O.J. Bakker A.C. van Lent P.L. Jacobs M.J. van den Berg W.B. Role of interleukin-1 in antigen-induced exacerbations of murine arthritis Am. J. Pathol. 146 1995 239-249.
27. Fantuzzi G.Dinarello C.A.The inflammatory response in IL-1β deficient mice. Comparison with other cytokine-related knock-out mice J. Leukoc. Biol. 59 1996 489-493.
28. van de Loo F.A.J. Joosten L.A.B. van Lent P.L. Arntz O.J. van den Berg W.B. Role of interleukin-1 tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis Arthritis Rheum. 38 1995 164-172.
29. Bresnihan B. Alvaro-Gracia J.M. Cobby M. Doherty M. Domljan Z. Emery P. Nuki G. Pavelka K. Rau R. Rozman B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist Arthritis Rheum. 41 1998 2196-2204.
30. Cohen S. Hurd E. Cush J. Schiff M. Weinblatt M. Moreland L. Kremer J. Bear M. Rich W. McCabe D. Treatment of rheumatoid arthritis with Anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate Arthritis Rheum. 46 2002 614-624.
31. Jiang Y. Genant H.K. Watt I. Cobby M. Bresnihan B. Aitchison R. McCabe D. A multicenter, double-blind, dose-ranging, randomised, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic progression and correlation of Genant and Larsen Scores Arthritis Rheum. 43 2000 1001-1009.
32. Choy E. Isenberg D. Garrood T. Farrow S. Ioannou Y. Bird H. Cheung N. Williams B. Hazleman B. Price R. Kishimoto T. The effect of anti-interleukin 6 (IL-6) receptor monoclonal antibody, MRA, in rheumatoid arthritis Ann. Rheum. Dis. 61Supp 1 2002 54.
33. Nishimoto N. Yoshizaki K. Miyasaka N. Yamamoto K. Kawai S. Takeuchi T. Hashimoto J. Azuma J. Kishimoto T. A multi-centre, randomised, double-blind, placebo-controlled trial of humanised anti-interleukin-6 receptor monoclonal antibody (MRA) in rheumatoid arthritis (RA) Arthritis Rheum. 46Supp 2002 S559.
34. Veys E.M. Menkes C.J. Emery P. A randomised double-blind study comparing L4 treatment with recombinant interferon gamma versus placebo in the treatment of RA Arthritis Rheum. 40 1997 62-68.
35. Sigidin Y. Loukina G. Skurkovich B. Skurkovich S. Randomised, double-blind trial of anti-interferon-γ antibodies in rheumatoid arthritis Scand. J. Rheum. 30 2001 203-207.
36. Taylor P.C. Williams R.O. Maini R.N. Immunotherapy for rheumatoid arthritis Curr. Opin. Immunol. 13 2001 611-616.
37. Mason U. Aldrich J. Breedveld F. Davis C.B. Elliot M. Jackson M. Jorgensen C. Keystone E. Levy R. Tesser J. et al. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis J. Rheumatol. 29 2002 220-229.
38. Kremer J. Westhovens R. Leon M. Di Georgio E. Alten R. Steinfeld S. Nuamah I. Becker J.-C. A phase 2B multi-centre, randomised, double-blind, placebo controlled study to evaluate the safety and efficacy of two different doses of CTLA4-Ig administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate Arthritis Rheum. 46Supp 2002 S203.
39. Emery P. Williams G. Li T. Nuamah I. Becker J.-C. Impact on health-related quality of life following treatment with CTLA4-Ig in patients with active rheumatoid arthritis using methotrexate Arthritis Rheum. 46Supp 2002 S515.
40. Weinblatt M. Schiff M. Goldman M. Kremer J .Breazna A. Becker J.-C. A pilot, multi-center, randomised, double-blind, placebo controlled study of a co-stimulation blocker CTLA4-Ig (2mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis Arthritis Rheum. 46Supp 2002 S204.
41. Emery P. Williams G. Li T. Breazna A. Becker J.-C. Improvement in health-related quality of life in patients with active rheumatoid arthritis: CTLA4-Ig combined with etanercept compared to etanercept plus placebo Arthritis Rheum. 46Supp 2002 S514.
42. Edwards J. Szczepanski L. Szechinski J. Filipowicz-Sosnowska A. Close D. Stevens R. Efficacy and safety of Rituximab, a B cell targeted chimeric monoclonal antibody: a randomised, placebo-controlled trial in patients with rheumatoid arthritis Arthritis Rheum. 46Supp 2002 S197.
43. Cambridge G. Leandro M. Edwards J. Ehrenstein M. Salden M. Webster D. B lymphocyte depletion in patients with rheumatoid arthritis: serial studies of immunological parameters Arthritis Rheum. 46Supp 2002 S506.